Amedica (AMDA) announced preliminary 1Q17 revenue of US $2.6MM, -37.7% vs. 1Q16, and 2Q17 revenue of $3.2MM, -20.0% vs. 2Q16, totaling preliminary 1H17 revenue of $5.8MM, -29.0% vs. 1H16.
The Taurus™ Pedicle Screw, FDA-cleared in 4Q16, has entered beta launch and generated $0.75MM in new revenue in 1H17. AMDA will release additional sets in 4Q17 to meet new surgeon customer demand. Overall, the company has achieved a 38% increase in surgeon users since the end of 2016.
Other highlights include a 14% increase in sales agents vs. year-end 2016, with many in previously unrepresented areas of the U.S., and the appointment of a new Area Vice President covering the southeast U.S.
On the R&D side, AMDA completed an initial friction and wear test of polished silicon nitride vs. native cartilage. Preliminary data show that silicon nitride is at least non-inferior in friction and wear performance compared to typical cobalt chrome alloys.
In 4Q16, AMDA re-filed an application with FDA for a modified porous (cancellous structured ceramic) cervical implant. Following a 510(k) pre-submission meeting, AMDA remains on track to file a 510(k) submission for a modified porous (cancellous structured ceramic) cervical implant in early 4Q17, based on FDA feedback.
Amedica (AMDA) announced preliminary 1Q17 revenue of US $2.6MM, -37.7% vs. 1Q16, and 2Q17 revenue of $3.2MM, -20.0% vs. 2Q16, totaling preliminary 1H17 revenue of $5.8MM, -29.0% vs. 1H16.
The Taurus™ Pedicle Screw, FDA-cleared in 4Q16, has entered beta launch and generated $0.75MM in new revenue in 1H17. AMDA will release additional sets in...
Amedica (AMDA) announced preliminary 1Q17 revenue of US $2.6MM, -37.7% vs. 1Q16, and 2Q17 revenue of $3.2MM, -20.0% vs. 2Q16, totaling preliminary 1H17 revenue of $5.8MM, -29.0% vs. 1H16.
The Taurus™ Pedicle Screw, FDA-cleared in 4Q16, has entered beta launch and generated $0.75MM in new revenue in 1H17. AMDA will release additional sets in 4Q17 to meet new surgeon customer demand. Overall, the company has achieved a 38% increase in surgeon users since the end of 2016.
Other highlights include a 14% increase in sales agents vs. year-end 2016, with many in previously unrepresented areas of the U.S., and the appointment of a new Area Vice President covering the southeast U.S.
On the R&D side, AMDA completed an initial friction and wear test of polished silicon nitride vs. native cartilage. Preliminary data show that silicon nitride is at least non-inferior in friction and wear performance compared to typical cobalt chrome alloys.
In 4Q16, AMDA re-filed an application with FDA for a modified porous (cancellous structured ceramic) cervical implant. Following a 510(k) pre-submission meeting, AMDA remains on track to file a 510(k) submission for a modified porous (cancellous structured ceramic) cervical implant in early 4Q17, based on FDA feedback.
Copy to clipboard 
